2017 Regulatory Data Shows a Friendlier FDA

article image

An innovation friendly FDA led to more device approvals and faster review times this year.

S ome 91% of PMAs (premarket applications) and panel-track supplements were approved by FDA in fiscal 2017 (ended September), the second highest approval rate since 2001; the pinnacle to date was 95% in 2015.

This article is restricted to subscribers only.

To continue reading, select one of the options below:

Existing Subscriber?

Sign In to continue reading.

Need Multi-User Access?

Gain access for your entire organization.

Get Quote Check to see if your company already has access

Subscribe to MedTech Strategist:

Actionable intelligence exploring the people, challenges, and opportunities impacting the global medtech community.

Subscribe to MedTech Strategist
Subscribe to ELITE Strategist

Become an ELITE Strategist and unlock access to both MedTech Strategist and MTS Market Pathways.

Subscribe to Elite


We're here to help! Please contact us at: